Rankings
▼
Calendar
SLDB Q3 2021 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena
SLDB
Solid Biosciences Inc.
$581M
Q3 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
Gross Profit
$4M
100.0% margin
Operating Income
-$18M
-509.8% margin
Net Income
-$18M
-508.4% margin
EPS (Diluted)
$-2.40
QoQ Revenue Growth
-1.6%
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$19M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$249M
Total Liabilities
$26M
Stockholders' Equity
$223M
Cash & Equivalents
$110M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4M
$0
—
Gross Profit
$4M
$0
—
Operating Income
-$18M
-$21M
+15.1%
Net Income
-$18M
-$21M
+15.4%
← FY 2021
All Quarters
Q4 2021 →